Sponsor or institution
Clinical trials and research at Natera, Inc.
As of November 12, 2026, Find a Trial lists 7 clinical trials run by Natera, Inc. that are recruiting, in United States. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| NMIBC sample collection to test cancer monitoring biomarkers | — | Austin, Texas | Recruiting | Aug 13, 2026 |
| Non-Hodgkin Lymphoma Sample Collection for MRD Testing | — | Austin, Texas | Recruiting | Aug 6, 2026 |
| Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection | — | Austin, Texas | Recruiting | Jan 5, 2026 |
| Signatera‑guided timing of CDK4/6 inhibitor (ribociclib) with hormone therapy for intermediate‑risk HR+/HER2‑ breast cancer | — | Phoenix, Arizona and 49 other locations | Recruiting | Oct 9, 2025 |
| Natera blood-based colorectal cancer screening for average-risk adults | — | Austin, Texas | Recruiting | Jul 1, 2025 |
| Developing a noninvasive prenatal test for single gene disorders | — | Glendale, Arizona and 17 other locations | Recruiting | Feb 5, 2025 |
| Collecting blood samples to develop a colorectal cancer screening test | — | Austin, Texas | Recruiting | Oct 1, 2024 |
All recruiting trials (7)
-
NMIBC sample collection to test cancer monitoring biomarkers
This study tests a blood, urine, and tumor tissue collection approach in people with high-risk non-muscle invasive bladder cancer to see if a molecular test can detect residual disease and monitor recurrence.
-
Non-Hodgkin Lymphoma Sample Collection for MRD Testing
This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.
-
Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection
This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.
-
Signatera‑guided timing of CDK4/6 inhibitor (ribociclib) with hormone therapy for intermediate‑risk HR+/HER2‑ breast cancer
This trial will test whether using Signatera ctDNA testing to time when to start a CDK4/6 inhibitor alongside hormone therapy can help adults with intermediate‑risk HR+/HER2‑ early breast cancer avoid unnecessary treatment while keeping cancer control.
-
Natera blood-based colorectal cancer screening for average-risk adults
This will test whether Natera's blood-based colorectal cancer screening can find cancer in average-risk adults who are planning a colonoscopy.
-
Developing a noninvasive prenatal test for single gene disorders
This study is testing a new blood test for pregnant women to see if it can safely check for serious genetic disorders in their babies, especially for those at higher risk.
-
Collecting blood samples to develop a colorectal cancer screening test
This study is collecting blood samples from people at average risk for colorectal cancer to see if they can create a new blood test for early detection of the disease.
Quick answers
How many clinical trials run by Natera, Inc. are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.